Rodrick MONTJEAN, Ph.D
R&D and preclinical development manager
44 years old
Driving License
Suresnes (92150) France
Employed
Open to opportunities
Strong background in bone diseases, virology, neurosciences, nephrology
Holder of a Ph.D in Biochemistry, Cellular and Molecular Biology, I have been focused on the preclinical development of therapeutic molecules, the elucidation of the mechanisms of action of these molecules and the discovery of the mechanisms involved in human pathologies (osteoarthritis, genetic brain and kidney diseases).
In this context, beyond technical skills, I have developed soft skills which allowed me to carry out the missions I have been entrusted :
The development of therapeutic molecules is still topical and remains a public health challenge in which I still want to get involved as a preclinical R&D project manager.
Holder of a Ph.D in Biochemistry, Cellular and Molecular Biology, I have been focused on the preclinical development of therapeutic molecules, the elucidation of the mechanisms of action of these molecules and the discovery of the mechanisms involved in human pathologies (osteoarthritis, genetic brain and kidney diseases).
In this context, beyond technical skills, I have developed soft skills which allowed me to carry out the missions I have been entrusted :
- Management skills :
- Supervision of CROs
- Coordination of expert networks
- Team supervision
- Scientific project management
- Communication skills :
- Reporting
- Written and oral presentation of data
- Redaction of scientific projects and documents
- Scientific skills :
- Study design
- Development of procedures
- Bibliographic and technological survey
- Project review
The development of therapeutic molecules is still topical and remains a public health challenge in which I still want to get involved as a preclinical R&D project manager.
R&D Project manager
REGULAXIS SAS
July 2017
to August 2021
Full-time
Romainville
France
- Missions :
- Preclinical phase management for the lead candidate molecule (REG-O3) in the frame of osteoarthritis therapeutics
- Identification of the competencies needed for the clinical phase and international network of experts implementation
- Clinical trial phase design in collaboration with the Chief Scientific Officer (CSO)
- Elucidation of the mechanism of action of REG-O3 internally
- Preclinical phase management for the lead candidate molecule (REG-O3) in the frame of osteoarthritis therapeutics
- Management skills :
- Search for CROs, academic collaborators and partnership with other SMEs
- Contracts set up and management
- Coordination of the international network for the writing of regulatory documents (study reports, IMPD)
- Team projects management
- Scientific project management (timelines, budget, risks)
- Quality control of the studies (GLP, GMP)
- Implementation of the quality system in the company
- Search for CROs, academic collaborators and partnership with other SMEs
- Communication skills :
- Projects reporting to the CSO, partners and collaborators
- Writing of a Scientific Technical Advice to the Belgian (FAMHP) and European (EMA) Health authorities
- Presentation and discussion of data at internal and international meetings
- Scientific documents redaction
- Writing of a scientific project for European funds (Eureka-Eurostars)
- Projects reporting to the CSO, partners and collaborators
- Scientific skills :
- Study plans definition and design
- Design and development of GLP experimental procedures
- Analyses and interpretation of results
- Team working and troubleshooting abilities
- Literature and technologic survey
- Review of scientific projects involving animals (member of the ethics committee on animal experimentation n°80)
- Study plans definition and design
Detailed Description
- Achievements:
• Management of an international network of 8 CROs, an in-house team of 2 engineers and 3 academic teams
• Design, follow-up and completion of 10 preclinical studies, including 3 regulatory studies (hemolytic test, PK/PD, toxicology)
• Review of 10 CRO study reports
• Writing and/or reviewing of 40 internal study reports
• Implementation of 20 internal procedures (SOPs)
• Preparation of a scientific and technical advice (STA) to Belgian and European health authorities
• Implementation of a corporate quality system and regular internal meetings
• Development of an animal model of traumatic osteoarthritis in collaboration with a CRO
• Review of 3 projects involving animals (member of the CEEA no. 80)
• Writing and publication of 1 article in the Plos One journal
• Writing of 4 annual reports, 9 abstracts and 5 posters
• 2 oral presentations in plenary sessions at international meetings (OARSI and ICRS)
• Preparation and submission of a project for European funding (Eureka-Eurostars: €1.9 M) - Trainings :- ISO 9001 quality systemOctober 2019
- Certificate of competence for animal experimentation - design and implementation of proceduresEcole nationale vétérinaire d'AlfortSeptember 2017
- Certificate of competence for animal experimentation - design and implementation of proceduresEcole nationale vétérinaire d'AlfortSeptember 2017
- Publication :- REG-O3 Chimeric Peptide Combining Growth Hormone and Somatostatin Sequences Improves Joint Function and Prevents Cartilage Degradation in Rat Model of Traumatic Knee Osteoarthritis.Rodrick Montjean, Sonia Escaich, Raffaello Paolini, Claude Carelli, Sébastien Pirson, Thibaut Neutelings, Yves Henrotin, Christelle Vêtu.
PLoS One. 2020 Apr14;15(4):e0231240.
https://pubmed.ncbi.nlm.nih.gov/32287299 - Oral Communications :- REG-O3 Chimeric Peptide combining Growth Hormone and Somatostatin sequences slows down Traumatic Knee Osteoarthritis Progression in Rat.Rodrick Montjean, Sonia Escaich, Raffaello Paolini, Claude Carelli, Yves Henrotin, Christelle Vêtu.
ICRS meeting 5th-8th october 2019 (Vancouver, Canada).
https://www.emedevents.com/c/medical-conferences-2019/icrs-2019-world-congress-vancouver
- New chimeric peptides regulating IGF-1 show significant therapeutic effect on anterior cruciate ligament transection rabbit model of osteoarthritis.Rodrick Montjean, Sonia Escaich, Raffaello Paolini, Claude Carelli, Yves Henrotin, Christelle Vêtu.
OARSI meeting 26th-29th april 2018 (Liverpool, UK).
https://www.oarsi.org/events/oarsi-2018-world-congress-0
- New chimeric peptides regulating IGF-1 show significant therapeutic effect on anterior cruciate ligament transection rabbit model of osteoarthritis.Rodrick Montjean, Sonia Escaich, Raffaello Paolini, Claude Carelli, Yves Henrotin, Christelle Vêtu.
- Poster Communications :
- New hope for knee osteoarthritis: IGF-1-regulating chimeric peptides showing therapeutic activity are well tolerated in vivo.Raffaello Paolini, Rodrick Montjean, Claude Carelli, Christelle Vêtu.
ICRS meeting 5th-8th october 2019 (Vancouver, Canada).
https://www.emedevents.com/c/medical-conferences-2019/icrs-2019-world-congress-vancouver
- Chimeric Peptide combining both Growth Hormone and Somatostatin sequences (REG-O3) Improves Function and Prevents Cartilage Degradation in Rat Model of Osteoarthritis.Rodrick Montjean, Sonia Escaich, Raffaello Paolini, Claude Carelli, Yves Henrotin, Christelle Vêtu.
OARSI meeting 2nd-5th may 2019 (Toronto, Canada).
https://www.oarsi.org/event/OARSI-2019-world-congress
- New hope for knee osteoarthritis: IGF-1-regulating chimeric peptides showing therapeutic activity on knee osteoarthritis are well tolerated in vivo. Raffaello Paolini, Rodrick Montjean, Claude Carelli, Christelle Vêtu.
26th Young Research Fellows meeting 20th-22nd february 2019 (Paris, France).
https://www.dndi.org/2019/media-centre/events/26th-young-research-fellows-meeting/
- Le peptide chimérique REG-O3 réduit la douleur et protège le cartilage chez le rat souffrant d’arthrose après méniscectomie partielle et section du ligament croisé.Rodrick Montjean, Sonia Escaich, Claude Carelli, Yves Henrotin, Christelle Vêtu.
31e congrès français de rhumatologie 9th-11th december 2018 (Paris, France).
https://sfr.larhumatologie.fr/agenda/31e-congres-francais-rhumatologie
- REG-O3, new chimeric peptides regulating IGF-1 pathway: significant therapeutic effect on ACLT rabbit model of osteoarthritis.Raffaello PAOLINI, Rodrick MONTJEAN and Christelle VETU.
ICRS meeting 9th-12th april 2018 (Macau, China).
https://10times.com/icrs-qa
- New hope for knee osteoarthritis: IGF-1-regulating chimeric peptides showing therapeutic activity are well tolerated in vivo.Raffaello Paolini, Rodrick Montjean, Claude Carelli, Christelle Vêtu.
Company Description
Based at BIOCITECH the technology park of life science of Paris North area. The company is engaged in the research, development and licensing of innovative synthetic molecules for use in human therapies. Its mission is to grant licenses of innovative molecules in a pharmaceutical company after the establishment of a phase II clinical record.
Company website
